Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cladribine + cytarabine + etoposide + venetoclax + fludarabine + busulfan + melphalan
- Development stage
- Unknown
- Lead developer
- Shanghai Jiao Tong University School of Medicine
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CALGE-VEN- RIC (more commonly referred to as CLAGE-VEN-RIC) is a sequential combination chemotherapy and reduced-intensity conditioning (RIC) regimen developed for the treatment of refractory acute myeloid leukemia (AML). The protocol involves a debulking phase consisting of the CLAGE-VEN regimen—comprising cladribine (a purine nucleoside analog), cytarabine (an antimetabolite), etoposide (a topoisomerase II inhibitor), and venetoclax (a BCL-2 inhibitor). This is followed by a reduced-intensity conditioning phase, typically consisting of fludarabine, busulfan, and melphalan (Flu-Bu-Mel) or total marrow irradiation (TMI), prior to allogeneic hematopoietic stem cell transplantation. The regimen is designed to improve remission rates in patients with highly resistant AML by combining traditional cytotoxic chemotherapy with targeted anti-apoptotic inhibition.
- Other names
- CLAGE-VEN sequential with RICCLAGE-VEN plus Flu-Bu-MelCLAGE-VEN and RIC for Refractory AML
02
Targets
Bcl-w (B-cell lymphoma 2-like 2)TOP2A (DNA topoisomerase II)DNADNA polymerase familyBCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on cladribine + cytarabine + etoposide + venetoclax + fludarabine + busulfan + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cladribine + cytarabine + etoposide + venetoclax + fludarabine + busulfan + melphalan.